Skip to main content
. 2021 Dec 9;37(2):273–284. doi: 10.1002/jbmr.4467

Fig. 2.

Fig. 2

Meta‐analysis of associations between sclerostin and cardiovascular disease risk factors, adjusted for age and ethnic group (ALSPAC) and sex (LURIC), body mass index, smoking, and social deprivation. Figure shows sclerostin vs. apolipoprotein A‐I, HDL and triglyceride levels (TG)(log) (SD change in outcome per SD increase in sclerostin, with 95% confidence intervals).